Oct 24th, Gelunhui: zai lab (ZLAB.US) soared 10.99% in pre-market trading to $32.12. On the news side, zai lab presented the ongoing study data of Zl-1310 at the EORTC- new china life insurance- AACR 2024 symposium, with an objective response rate (ORR) of 74% at all tested dose levels in patients with recurrent extensive-stage small cell lung cancer (SCLC). In addition, jpmorgan raised zai lab's target price from $38 to $44. (Gelunhui)
美股异动丨再鼎医药盘前大涨10% 获摩根大通上调目标价
U.S. stock market anomaly: zai lab surged 10% before the market opened and received a target price increase from jpmorgan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated